Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Zappasodi

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Science (New York, N.Y.)|March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerNaiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.
Cancer Immunology Research|April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint InhibitorsMaria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
Nature|February 15, 2021
CTLA-4 blockade drives loss of T<sub>reg</sub> stability in glycolysis-low tumoursRoberta Zappasodi, Inna Serganova, Ivan J Cohen, et al.
The Journal of Clinical Investigation|September 15, 2022
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockadeArnab Ghosh, Judith Michels, Riccardo Mezzadra, et al.
Immunity|June 8, 2021
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8<sup>+</sup> T cells in tumorsShihao Xu, Omkar Chaudhary, Patricia Rodríguez-Morales, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Cancer Immunology Research|September 21, 2021
Supporting the Next Generation of Scientists to Lead Cancer Immunology ResearchElise Alspach, Ryan D Chow, Shadmehr Demehri, et al.
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Research Square|April 2, 2024
Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphomaValeria Cancila, Gaia Morello, Giorgio Bertolazzi, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Science (New York, N.Y.)|March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerNaiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.
Cancer Immunology Research|April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint InhibitorsMaria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
Nature|February 15, 2021
CTLA-4 blockade drives loss of T<sub>reg</sub> stability in glycolysis-low tumoursRoberta Zappasodi, Inna Serganova, Ivan J Cohen, et al.
The Journal of Clinical Investigation|September 15, 2022
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockadeArnab Ghosh, Judith Michels, Riccardo Mezzadra, et al.
Immunity|June 8, 2021
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8<sup>+</sup> T cells in tumorsShihao Xu, Omkar Chaudhary, Patricia Rodríguez-Morales, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Cancer Immunology Research|September 21, 2021
Supporting the Next Generation of Scientists to Lead Cancer Immunology ResearchElise Alspach, Ryan D Chow, Shadmehr Demehri, et al.
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Research Square|April 2, 2024
Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphomaValeria Cancila, Gaia Morello, Giorgio Bertolazzi, et al.
Pageof 7